Project details


Long-term and late side-effects of immunotherapy in melanoma and NSCLC patients surviving more than 2 years after immunotherapy

immunotherapy oncology Survivor care

Dr. J. Nuver
A. Eggen

Nature of the research:
The aim of this study is to investigate the long-term and late side-effects of immunotherapy in melanoma and non-small cell lung cancer (NSCLC) patients surviving ≥ 2 years after the first cycle of immunotherapy.

Fields of study:
oncology rehabilitation internal medicine

Background / introduction
Tremendous anti-tumour effects have been achieved using immunotherapy for various cancers in recent years. In patients with NSCLC and melanoma long-lasting responses of more than 2 years (or even cure) occur in a substantial subgroup of patients. Overwhelmed by early successes of this approach, still little is known about the long-term and late side-effects of immunotherapy. A careful and thorough assessment of the long-term burden of disease and treatment toxicity is required to inform and implement adequate follow-up strategies.
Research question / problem definition
To investigate quality of life of patients surviving more than 2 years after immunotherapy. Moreover, we will investigate the cognitive function, endocrine function, physical fitness and psychological functioning in the study population.
All participants have a single study visit, which will take place at the medical oncology clinic in the UMCG. During this single study visit, all study measures will be completed. The study already started in October 2018, and patient accrual is still ongoing.

Research student:
As a research student, you will be asked to participate in all aspects of the study; inform and include patients, administer the study measures, fill the research database and analyse and interpret the results. Weekly supervision meeting will be scheduled to discuss any questions and your progress.

If you are interested or would like to gain more information about this project, please contact Dr Janine Nuver:
1. Gettinger SN, Horn L, Gandhi L, et al. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (2015). Journal of Clinical Oncology; 33, 2004-2012.
2. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma (2015). The New England Journal of Medicine; 372, 2006-2017.
3. Maio M, Grob JJ, Aamdal S, et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial (2015). Journal of Clinical Oncology; 33, 1191-1196.
4. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology (1993). J Natl Cancer Inst; 85 :365-376.
back to toptop